|
1
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Huang J, Liu K, Song D, Ding M, Wang J,
Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group
box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer
Sci. 107:242–249. 2016. View Article : Google Scholar :
|
|
3
|
Sun Y, He N, Dong Y and Jiang C:
MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin
treatment in osteosarcoma. Sci Rep. 6:342382016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shackleton M, Quintana E, Fearon ER and
Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus
clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Clarke MF and Fuller M: Stem cells and
cancer: Two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Martins-Neves SR, Paiva-Oliveira DI,
Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JV,
Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in
osteosarcoma cells through activation of Wnt/β-catenin signaling.
Cancer Lett. 370:286–295. 2016. View Article : Google Scholar
|
|
7
|
Yang J, Guo W, Wang L, Yu L, Mei H, Fang
S, Ji P, Liu Y, Liu G and Song Q: Cisplatin-resistant osteosarcoma
cells possess cancer stem cell properties in a mouse model. Oncol
Lett. 12:2599–2605. 2016.PubMed/NCBI
|
|
8
|
Gonçalves C, Martins-Neves SR,
Paiva-Oliveira D, Oliveira VE, Fontes-Ribeiro C and Gomes CM:
Sensitizing osteosarcoma stem cells to doxorubicin-induced
apoptosis through retention of doxorubicin and modulation of
apoptotic-related proteins. Life Sci. 130:47–56. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ni M, Xiong M, Zhang X, Cai G, Chen H,
Zeng Q and Yu Z: Poly(lactic-co-glycolic acid) nanoparticles
conjugated with CD133 aptamers for targeted salinomycin delivery to
CD133+ osteosarcoma cancer stem cells. Int J
Nanomedicine. 10:2537–2554. 2015. View Article : Google Scholar :
|
|
10
|
Feng X, Jiang J, Shi S, Xie H, Zhou L and
Zheng S: Knockdown of miR-25 increases the sensitivity of liver
cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad
signaling pathway. Int J Oncol. 49:2600–2610. 2016.PubMed/NCBI
|
|
11
|
Chen Y, Zhang F, Tsai Y, Yang X, Yang L,
Duan S, Wang X, Keng P and Lee SO: IL-6 signaling promotes DNA
repair and prevents apoptosis in CD133+ stem-like cells
of lung cancer after radiation. Radiat Oncol. 10:2272015.
View Article : Google Scholar
|
|
12
|
Adler AI, Shaw EJ, Stokes T and Ruiz F;
Guideline Development Group: Newer agents for blood glucose control
in type 2 diabetes: Summary of NICE guidance. BMJ. 338:b16682009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tseng CH: Metformin reduces thyroid cancer
risk in Taiwanese patients with type 2 diabetes. PLoS One.
9:e1098522014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dowling RJ, Niraula S, Stambolic V and
Goodwin PJ: Metformin in cancer: Translational challenges. J Mol
Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhao W, Zhang X, Liu J, Sun B, Tang H and
Zhang H: miR-27a-mediated antiproliferative effects of metformin on
the breast cancer cell line MCF-7. Oncol Rep. 36:3691–3699.
2016.PubMed/NCBI
|
|
16
|
Franciosi M, Lucisano G, Lapice E,
Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and
risk of cancer in patients with type 2 diabetes: Systematic review.
PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
El-Mir MY, Nogueira V, Fontaine E, Avéret
N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell
respiration via an indirect effect targeted on the respiratory
chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Silvestri A, Palumbo F, Rasi I, Posca D,
Pavlidou T, Paoluzi S, Castagnoli L and Cesareni G: Metformin
induces apoptosis and downregulates pyruvate kinase M2 in breast
cancer cells only when grown in nutrient-poor conditions. PLoS One.
10:e01362502015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang W and Lu Z: Regulation and function
of pyruvate kinase M2 in cancer. Cancer Lett. 339:153–158. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
He Y, Wang Y, Liu H, Xu X, He S, Tang J,
Huang Y, Miao X, Wu Y, Wang Q, et al: Pyruvate kinase isoform M2
(PKM2) participates in multiple myeloma cell proliferation,
adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Dayton TL, Jacks T and Vander Heiden MG:
PKM2, cancer metabolism, and the road ahead. EMBO Rep.
17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garber K: Energy deregulation: Licensing
tumors to grow. Science. 312:1158–1159. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Zhou Y, Tozzi F, Chen J, Fan F, Xia L,
Wang J, Gao G, Zhang A, Xia X, Brasher H, et al: Intracellular ATP
levels are a pivotal determinant of chemoresistance in colon cancer
cells. Cancer Res. 72:304–314. 2012. View Article : Google Scholar
|
|
24
|
Ren XF, Mu LP, Jiang YS, Wang L and Ma JF:
LY2109761 inhibits metastasis and enhances chemosensitivity in
osteosarcoma MG-63 cells. Eur Rev Med Pharmacol Sci. 19:1182–1190.
2015.PubMed/NCBI
|
|
25
|
Yang Q, Zhang S, Kang M, Dong R and Zhao
J: Synergistic growth inhibition by sorafenib and cisplatin in
human osteosarcoma cells. Oncol Rep. 33:2537–2544. 2015.PubMed/NCBI
|
|
26
|
Davis W Jr, Ronai Z and Tew KD: Cellular
thiols and reactive oxygen species in drug-induced apoptosis. J
Pharmacol Exp Ther. 296:1–6. 2001.
|
|
27
|
Casares C, Ramírez-Camacho R, Trinidad A,
Roldán A, Jorge E and García-Berrocal JR: Reactive oxygen species
in apoptosis induced by cisplatin: Review of physiopathological
mechanisms in animal models. Eur Arch Otorhinolaryngol.
269:2455–2459. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao JZ, Chen FH, Wang L, Wei H and Meng
SL: YM155 inhibits tumor growth and enhances chemosensitivity to
cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci. 19:2062–2069.
2015.PubMed/NCBI
|
|
29
|
Liu J, Tang Q, Li S and Yang X: Inhibition
of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal
cancer stem cells. Oncotarget. 7:86446–86456. 2016.PubMed/NCBI
|
|
30
|
Abarrategi A, Tornin J, Martinez-Cruzado
L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini
N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-origin,
cancer stem cells, and targeted therapies. Stem Cells Int.
2016:36317642016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li Z, Yang P and Li Z: The multifaceted
regulation and functions of PKM2 in tumor progression. Biochim
Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
|
|
32
|
He J, Xie G, Tong J, Peng Y, Huang H, Li
J, Wang N and Liang H: Overexpression of microRNA-122 re-sensitizes
5-FU-resistant colon cancer cells to 5-FU through the inhibition of
PKM2 in vitro and in vivo. Cell Biochem Biophys. 70:1343–1350.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He Y, Wang Y, Liu H, Xu X, He S, Tang J,
Huang Y, Miao X, Wu Y, Wang Q, et al: Pyruvate kinase isoform M2
(PKM2) participates in multiple myeloma cell proliferation,
adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Chen G, Feng W, Zhang S, Bian K, Yang Y,
Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer
via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res.
5:1423–1434. 2015.
|
|
35
|
Longley DB and Johnston PG: Molecular
mechanisms of drug resistance. J Pathol. 205:275–292. 2005.
View Article : Google Scholar : PubMed/NCBI
|
